Literature DB >> 8094982

Growth factor gene expression in kidney of murine polycystic kidney disease.

T Nakamura1, I Ebihara, I Nagaoka, Y Tomino, S Nagao, H Takahashi, H Koide.   

Abstract

The DBA/2FG-pcy mouse has a form of slowly progressive kidney disease that appears similar in many respects to that seen in the autosomal dominant form of human polycystic kidney disease. The aim of this study was to examine the mRNA expression of growth-related proteins in kidney obtained from DBA/2FG-pcy mice and control DBA/2 mice at 8, 16, and 30 wk of age. The mRNA levels encoding for proliferating cell nuclear antigen (PCNA), transforming growth factor (TGF)-beta, platelet-derived growth factor (PDGF)-A and PDGF-B chains, insulin-like growth factor (IGF)-I, and basic fibroblast growth factor (bFGF) were increased with the progression of cystic lesions in the kidneys of DBA/2FG-pcy mice. At 30 wk of age, mRNA levels of PCNA, TGF-beta, PDGF-A and PDGF-B chains, IGF-I, and bFGF were increased 5.4-fold, 4.8-fold, 4.4-fold, 3.8-fold, 3.7-fold, and 4.6-fold, respectively, compared with those of control DBA/2 mice. In contrast, mRNA levels for epidermal growth factor in kidney of DBA/2FG-pcy mice decreased with age as compared with those of DBA/2 mice. These results suggest that decreased epidermal growth factor mRNA expression and increased expression of PCNA, TGF-beta, PDGF-A and PDGF-B chains, IGF-I, and bFGF mRNA may contribute to the progression of cystic lesions in DBA/2FG-pcy mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094982     DOI: 10.1681/ASN.V371378

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 3.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system.

Authors:  E Parker; L J Newby; C C Sharpe; S Rossetti; A J Streets; P C Harris; M J O'Hare; A C M Ong
Journal:  Kidney Int       Date:  2007-03-28       Impact factor: 10.612

5.  Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Authors:  Vicente E Torres; Arlene B Chapman; Ronald D Perrone; K Ty Bae; Kaleab Z Abebe; James E Bost; Dana C Miskulin; Theodore I Steinman; William E Braun; Franz T Winklhofer; Marie C Hogan; Frederic R Oskoui; Cass Kelleher; Amirali Masoumi; James Glockner; Neil J Halin; Diego R Martin; Erick Remer; Nayana Patel; Ivan Pedrosa; Louis H Wetzel; Paul A Thompson; J Philip Miller; Catherine M Meyers; Robert W Schrier
Journal:  Kidney Int       Date:  2011-12-28       Impact factor: 10.612

Review 6.  Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Sonu Kashyap; Julianna D Zeidler; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Cell Signal       Date:  2020-06-20       Impact factor: 4.315

Review 7.  Novel targets for the treatment of autosomal dominant polycystic kidney disease.

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Expert Opin Investig Drugs       Date:  2010-03       Impact factor: 6.206

8.  Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.

Authors:  Sonu Kashyap; Kyaw Zaw Hein; Claudia Cs Chini; Jorgo Lika; Gina M Warner; Laurie K Bale; Vicente E Torres; Peter C Harris; Claus Oxvig; Cheryl A Conover; Eduardo N Chini
Journal:  JCI Insight       Date:  2020-02-27

9.  In situ loading of basic fibroblast growth factor within porous silica nanoparticles for a prolonged release.

Authors:  Jin Zhang; Lynne-Marie Postovit; Dashan Wang; Richard B Gardiner; Richard Harris; Muminmd Abdul; Anualice Thomas
Journal:  Nanoscale Res Lett       Date:  2009-07-25       Impact factor: 4.703

10.  Constitutive renal Rel/nuclear factor-κB expression in Lewis polycystic kidney disease rats.

Authors:  Michelle H T Ta; Kristina G Schwensen; David Liuwantara; David L Huso; Terry Watnick; Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.